| The Hippo pathway and human cancer KF Harvey, X Zhang, DM Thomas Nature Reviews Cancer 13 (4), 246-257, 2013 | 1889 | 2013 |
| Translational biology of osteosarcoma M Kansara, MW Teng, MJ Smyth, DM Thomas Nature Reviews Cancer 14 (11), 722-735, 2014 | 1091 | 2014 |
| Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study D Thomas, R Henshaw, K Skubitz, S Chawla, A Staddon, JY Blay, ... The lancet oncology 11 (3), 275-280, 2010 | 748 | 2010 |
| The distinctive biology of cancer in adolescents and young adults A Bleyer, R Barr, B Hayes-Lattin, D Thomas, C Ellis, B Anderson, ... Nature Reviews Cancer 8 (4), 288-298, 2008 | 745 | 2008 |
| Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study S Chawla, R Henshaw, L Seeger, E Choy, JY Blay, S Ferrari, J Kroep, ... The lancet oncology 14 (9), 901-908, 2013 | 610 | 2013 |
| Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone DG Branstetter, SD Nelson, JC Manivel, JY Blay, S Chawla, DM Thomas, ... Clinical Cancer Research 18 (16), 4415-4424, 2012 | 465 | 2012 |
| Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2 E Zelzer, DJ Glotzer, C Hartmann, D Thomas, N Fukai, S Soker, BR Olsen Mechanisms of development 106 (1-2), 97-106, 2001 | 444 | 2001 |
| The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation DM Thomas, SA Carty, DM Piscopo, JS Lee, WF Wang, WC Forrester, ... Molecular cell 8 (2), 303-316, 2001 | 439 | 2001 |
| Clinical overview of MDM2/X-targeted therapies A Burgess, KM Chia, S Haupt, D Thomas, Y Haupt, E Lim Frontiers in oncology 6, 7, 2016 | 377 | 2016 |
| High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer M Krypuy, GM Newnham, DM Thomas, M Conron, A Dobrovic BMC cancer 6, 1-12, 2006 | 374 | 2006 |
| FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor V Guagnano, A Kauffmann, S Wöhrle, C Stamm, M Ito, L Barys, A Pornon, ... Cancer discovery 2 (12), 1118-1133, 2012 | 353 | 2012 |
| Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice M Kansara, M Tsang, L Kodjabachian, NA Sims, MK Trivett, M Ehrich, ... The Journal of clinical investigation 119 (4), 837-851, 2009 | 335 | 2009 |
| Molecular pathogenesis of osteosarcoma M Kansara, DM Thomas DNA and cell biology 26 (1), 1-18, 2007 | 331 | 2007 |
| Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial WD Tap, H Gelderblom, E Palmerini, J Desai, S Bauer, JY Blay, T Alcindor, ... The Lancet 394 (10197), 478-487, 2019 | 320 | 2019 |
| Li-Fraumeni syndrome: cancer risk assessment and clinical management KA McBride, ML Ballinger, E Killick, J Kirk, MHN Tattersall, RA Eeles, ... Nature reviews Clinical oncology 11 (5), 260-271, 2014 | 278 | 2014 |
| Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis PA Cassier, H Gelderblom, S Stacchiotti, D Thomas, RG Maki, JR Kroep, ... Cancer 118 (6), 1649-1655, 2012 | 272 | 2012 |
| Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing SQ Wong, J Li, AYC Tan, R Vedururu, JMB Pang, H Do, J Ellul, K Doig, ... BMC medical genomics 7, 1-10, 2014 | 264 | 2014 |
| Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma DM Thomas, SA Johnson, NA Sims, MK Trivett, JL Slavin, BP Rubin, ... The Journal of cell biology 167 (5), 925-934, 2004 | 253 | 2004 |
| Starting an adolescent and young adult program: some success stories and some obstacles to overcome A Ferrari, D Thomas, ARK Franklin, BM Hayes-Lattin, M Mascarin, ... Journal of Clinical Oncology 28 (32), 4850-4857, 2010 | 250 | 2010 |
| Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial LA Chantrill, AM Nagrial, C Watson, AL Johns, M Martyn-Smith, ... Clinical cancer research 21 (9), 2029-2037, 2015 | 240 | 2015 |
Mandy and BallingerGroup Leader, Genetic Cancer Risk, Garvan Institute of Medical ResearchVerified email at garvan.org.au
